Vienna - Delayed Quote EUR

argenx SE (ARGX.VI)

642.80

+10.20

+(1.61%)

At close: January 31 at 3:30:34 PM GMT+1

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks yesterday

ARGX
Exploring High Growth Tech Stocks With Promising Potential

As global markets experience a surge, with U.S. stocks reaching new heights amid optimism over trade policies and AI advancements, growth stocks have notably outperformed their value counterparts, highlighting investor enthusiasm for innovation-driven sectors. In this dynamic environment, identifying high-growth tech stocks involves evaluating companies that can leverage technological advancements and strategic partnerships to capitalize on emerging market opportunities.

Simply Wall St. yesterday

ARGNF

ARGX
Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other high growth international stocks to invest in now. What To Expect From The Stock Market in 2025? On January 15, Jurrien Timmer, […]

Insider Monkey 8 days ago

ARGX
Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other high growth international stocks to invest in now. What To Expect From The Stock Market in 2025? On January 15, Jurrien […]

Insider Monkey 8 days ago

ASND

ARGX
Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks 14 days ago

ARGX
argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and

GlobeNewswire 18 days ago

ARGNF

ARGX
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl

GlobeNewswire 25 days ago

ARGNF

ARGX
Exploring High Growth Tech Stocks for January 2025

As we enter January 2025, global markets are navigating a landscape marked by fluctuating consumer confidence and mixed economic indicators, with major U.S. stock indexes experiencing moderate gains amidst a holiday-shortened trading week. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential and market adaptability, particularly as the technology-heavy Nasdaq Composite continues to show resilience despite recent...

Simply Wall St. 30 days ago

ARGNF

ARGX
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

Argenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements i

TipRanks last month

ARGNF

ARGX
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of

GlobeNewswire last month

ARGNF

ARGX
Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […]

Insider Monkey last month

ARGX
Here’s Why argenx SE (ARGX) Surged in Q3

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […]

Insider Monkey last month

ARGX
Should You Increase Your Holdings in argenx SE (ARGX)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96% (gross) and […]

Insider Monkey last month

ARGX
Three Stocks Estimated To Be Undervalued In December 2024

As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.

Simply Wall St. last month

SWEC-A.ST

SWEC-B.ST

ESRCF
Spotlight On High Growth Tech Stocks This December 2024

As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes.

Simply Wall St. last month

ARGNF

ARGX

GTK.NZ
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […]

Insider Monkey last month

ARGX
argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wedn

GlobeNewswire 2 months ago

ARGNF

ARGX
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

BioPharma Dive 2 months ago

HALO

EVT.DE

ARGX
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease

GlobeNewswire 2 months ago

ARGNF

ARGX
Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]

Insider Monkey 2 months ago

ARGX

Performance Overview

Return	ARGX.VI	BEL 20
YTD	+7.78%	+2.37%
1-Year	+90.46%	+18.72%
3-Year	+182.67%	+6.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

argenx SE (ARGX.VI)

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Exploring High Growth Tech Stocks With Promising Potential

Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks for January 2025

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

Here’s Why argenx SE (ARGX) Surged in Q3

Should You Increase Your Holdings in argenx SE (ARGX)?

Three Stocks Estimated To Be Undervalued In December 2024

Spotlight On High Growth Tech Stocks This December 2024

Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

argenx to Present at Upcoming Investor Conferences

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?

Performance Overview